- Home
- TNGX vs UTG Comparison
TNGX vs UTG Comparison
Compare TNGX & UTG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TNGX | UTG |
|---|---|---|
| Founded | 2014 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 3.3B |
| IPO Year | 2020 | 2003 |
Fundamental Metrics
Financial Performance| Metric | TNGX | UTG |
|---|---|---|
| Price | $23.47 | $33.69 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 13 | 0 |
| Target Price | ★ $44.88 | N/A |
| AVG Volume (30 Days) | ★ 3.5M | 324.9K |
| Earning Date | 11-03-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 26.89 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $62,384,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 48.29 | N/A |
| 52 Week Low | $7.12 | $33.53 |
| 52 Week High | $34.39 | $43.90 |
Technical Indicators
Market Signals| Indicator | TNGX | UTG |
|---|---|---|
| Relative Strength Index (RSI) | 47.72 | 31.62 |
| Support Level | $20.46 | $33.53 |
| Resistance Level | $25.68 | $41.06 |
| Average True Range (ATR) | 1.78 | 0.73 |
| MACD | 0.35 | -0.11 |
| Stochastic Oscillator | 33.57 | 5.50 |
Price Performance
Historical ComparisonAbout TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
About UTG Reaves Utility Income Fund of Beneficial Interest
Reaves Utility Income Fund is a closed-end management investment company. The company's investment objective is to provide a high level of after-tax income and total return consisting of tax-advantaged dividend income and capital appreciation. It invests a portion of its total assets in securities of utility companies, which may include companies in the electric, gas, water, telecommunications sectors, as well as other companies engaged in other infrastructure operations.